Treatment of relapses of gestational trophoblastic neoplasias

Cover Page

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The purpose of the study: to present an experience of the N. N. Blokhin Russian Cancer Research Center in the treatment of relapses of gestational trophoblastic neoplasias (GTN).

Materials and methods. We performed a retrospective analysis of medical case histories at the N. N. Blokhin Russian Cancer Research Center from 1996 until 2019. 545 patients with GTN were treated. Relapses occurred in 25 (4.6%) patients: 8 (2.1%) patients with low risk of resistance (6 (75%) – early relapses and 2 (25%) – late relapses) and 17 (10%) patients with high risk of resistance (11 (65%) – early relapses and 6 (35%) – late relapses). Treatment of relapses was done by standard chemotherapy regimens (Dactinomycin 500mcg in days 1–5, EMA-CO, EMA-EP). Different surgical interventions and radiosurgery were used in some cases additionally.

Results. Out of 6 patients with early relapses of low-risk GTN, 5 were cured with chemotherapy and one patient by lung resection only. Two patients with late relapses of low-risk GTN were cured with chemotherapy (EMA-CO) and hysterectomy/resection of uterus to achieve complete remission. As a result, all patients with relapses of low-risk GTN were cured, mainly (88%) by chemotherapy. Among 11 patients with early relapses of high-risk GTN, complete remission was achieved in 6 (55%) cases: in 2 patients as a result of EMA-EP chemotherapy, other patients needed combined approaches (chemotherapy + surgery). Three patients with recurrent course continue treatment, two patients died of progression. Of the 6 patients with late relapses of high-risk GTN, 4 (66%) patients were managed mainly through combined treatment (surgery + chemotherapy) and were cured. One patient continues treatment for more than 4 years, and one patient died of progression. In total, out of 17 patients with high-risk relapses, complete remission was achieved in 10 (59%) as a result of combined treatment in the majority of cases (80%).

Conclusion. The optimal method of treatment for patients with relapses of low-risk GTN is chemotherapy; and for high-risk GTN – combined approaches (chemotherapy + surgery)

Full Text

Restricted Access

About the authors

L. A. Meshcheryakova

N.N. Blokhin Russian Cancer Research Center

Author for correspondence.
Email: 2010am@mail.ru
ORCID iD: 0000-0001-8479-3615
Russian Federation, 115478, Moscow

A. S. Zharova

N.N. Blokhin Russian Cancer Research Center

Email: 2010am@mail.ru
ORCID iD: 0000-0001-8591-3797
Russian Federation, 115478, Moscow

A. F. Maslennikov

N.N. Blokhin Russian Cancer Research Center

Email: 2010am@mail.ru
ORCID iD: 0000-0003-3959-3133
Russian Federation, 115478, Moscow

V. V. Kuznetsov

N.N. Blokhin Russian Cancer Research Center

Email: 2010am@mail.ru
Russian Federation, 115478, Moscow

M. A. Chekalova

N.N. Blokhin Russian Cancer Research Center

Email: 2010am@mail.ru
Russian Federation, 115478, Moscow

I. G. Komarov

N.N. Blokhin Russian Cancer Research Center

Email: 2010am@mail.ru
Russian Federation, 115478, Moscow

I. Yu. Davydova

N.N. Blokhin Russian Cancer Research Center

Email: 2010am@mail.ru
Russian Federation, 115478, Moscow

G. V. Molchanov

N.N. Blokhin Russian Cancer Research Center

Email: 2010am@mail.ru
Russian Federation, 115478, Moscow

N. M. Gigolaeva

N.N. Blokhin Russian Cancer Research Center

Email: 2010am@mail.ru
Russian Federation, 115478, Moscow

A. A. Meshcheryakov

N.N. Blokhin Russian Cancer Research Center

Email: 2010am@mail.ru
Russian Federation, 115478, Moscow

References

  1. Wang J., Short D., Sebire N. J. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann. Oncol. 2008; 19 (9): 1578–83. doi: 10.1093/annonc/mdn181.
  2. Seckl M.J., Sebire N.J., Fisher R.A., Golfier F., Massuger L., Sessa C. Gestational trophoblastic disease: ESMO clinical practice: guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013; 24 (Suppl 6): vi39–vi50.
  3. Shih I.M. Gestational trophoblastic neoplasia – pathogenesis and potential therapeutic targets. Lancet Oncol. 2007; 8 (7): 642–50.
  4. Meshcheryakova L.A., Kozachenko V.P., Kuznetsov V.V. Trophoblastic disease. Clinical Oncogynecology: A Guide for Physicians. 2nd. Moscow: Binom; 2016. (In Russian)
  5. Meshcheryakova L. A. Trophoblastic disease. Tumors of the female reproductive system. 2014; 4: 74–86. (In Russian)
  6. Mutch D.G., Soper J.T., Babcock C.J. Recurrent gestational trophoblastic disease. Experience of the Southeastern Regional Trophoblastic Disease Center. Cancer. 1990; 66: 978–82.
  7. Newlands E.S., Bagshawe K.D., Begent R.H. Results with the EMA/CO (etoposide, methotrexate,actinomycin D, cyclophosphamide,vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br. J. Obstet. Gynaecol. 1991; 98: 550–7.
  8. Soper J.T. Surgical therapy for gestational trophoblastic disease. J. Reprod. Med. 1994; 39: 168–74.
  9. Goldstein D.P., Berkowitz R.S. Prophylactic chemotherapy of complete molar pregnancy. Semin. Oncol. 1995; 22: 157–60.
  10. Ngan H.Y., Tam K.F., Lam K.W., Chan K.K. Relapsed gestational trophoblastic neoplasia: a 20-year experience. J. Reprod. Med. 2006; 51 (10): 829–34.
  11. Wong L.C., Choo Y.C., Ma H.K. Hepatic metastases in gestational trophoblastic disease. Obstet. Gynecol. 1986; 67: 107–11.
  12. Horowitz N.S., Goldstein D.P., Berkowitz R.S. Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities. Gynecol. Oncol. 2017; 144: 208–14.
  13. Lurain J.R., Singh D.K., Schink J.C. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J. Reprod. Med. 2006; 51: 767–72.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 86496 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ЭЛ № ФС 77 - 80673 от 23.03.2021 г
.



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies